Literature DB >> 12954916

Behavioral implications of lowering cholesterol levels: a double-blind pilot study.

Tom Ormiston1, Owen M Wolkowitz, Victor I Reus, Francesca Manfredi.   

Abstract

The treatment of hypercholesterolemia may be associated with greater noncardiac mortality. This current pilot study sought to determine which behaviors, if any, are associated with decreases in cholesterol level. Twelve subjects received one of two cholesterol-reducing drugs or placebo. Cholesterol and behavioral ratings were measured at baseline, 4, and 52 weeks with standardized scales. Cholesterol levels markedly declined with concomitant significant increases in impulsivity ratings at 4 weeks. At 52 weeks, the increase in impulsivity ratings was no longer apparent, but depression ratings showed a significant improvement. This pilot study, although limited in size, raises the possibility that cholesterol-lowering drugs are associated with mild, time-limited increases in impulsivity and with mild, time-delayed improvements in depression ratings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954916     DOI: 10.1176/appi.psy.44.5.412

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa?

Authors:  Jess G Fiedorowicz; William G Haynes
Journal:  Curr Psychiatr       Date:  2010-07

2.  Psychologic disorders and statin use: a propensity score-matched analysis.

Authors:  Ishak Mansi; Christopher R Frei; Mary J Pugh; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2013-04-26       Impact factor: 4.705

Review 3.  Statins, mood, sleep, and physical function: a systematic review.

Authors:  Kristopher J Swiger; Raoul J Manalac; Michael J Blaha; Roger S Blumenthal; Seth S Martin
Journal:  Eur J Clin Pharmacol       Date:  2014-10-08       Impact factor: 2.953

Review 4.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Kirsten Ward; Theresa Hm Moore; Margaret Burke; George Davey Smith; Juan-Pablo Casas; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 5.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 6.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 7.  Screening, diagnosis & monitoring of depression/distress in CHF patients.

Authors:  Mark W Ketterer; Walter Knysz
Journal:  Heart Fail Rev       Date:  2007-08-01       Impact factor: 4.214

8.  Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort.

Authors:  Liang Feng; Chay-Hoon Tan; Reshma A Merchant; Tze-Pin Ng
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.

Authors:  Michele L Pucak; Katherine A L Carroll; Douglas A Kerr; Adam I Kaplin
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 10.  The impact of statins on psychological wellbeing: a systematic review and meta-analysis.

Authors:  Adrienne O'Neil; Livia Sanna; Cassie Redlich; Kristy Sanderson; Felice Jacka; Lana J Williams; Julie A Pasco; Michael Berk
Journal:  BMC Med       Date:  2012-12-03       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.